1. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology 2005; 2–10.
2. Leuven SI, Franssen R, Kastelein JJ et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008; 47: 3–7.
3. Насонов Е.Л. Иммунологические маркеры атеросклероза. Тер. арх. 2002; 5: 80–5.
4. Ross R. Atherosclerosisan inflammatory disease. N Engl J Med 1999; 340: 115–126.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–43.
6. Ревматология: национальное руководство. Под ред. Е.Л.Насонова, В.А.Насоновой М.: Гэотар-Медиа, 2008; 647–60.
7. Goodson NJ, Wiles NJ, Lunt M et al. Mortality in early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010–9.
8. Mansi S, Meilahn E, Rairie J et al. Age specific incidence rates of myocardial infarction angina in women with systemic lupus erythematosus: comparison with the Framingem study. Am J Epidemiol 1997; 145: 408–15.
9. Kremers MH, Crowson C, Nicola P et al. Increased unrecognized coronary heart disease and sudden deaths rheumatoid arthritis. A population-based controlled study. Arthritis Rheum 2005; 52: 402–11.
10. Kremers MH, Nicola P, Crowson C et al. Cardiovascular death in rheumatoid arthritis. Arthritis Rheum 2005; 52: 722–32.
11. Aubry M-C, Kremers MH, Reinalda MC et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatology 2007; 34: 937–42.
12. Abu-Shakra M, Urowitz MB, Gladman DD et al. Mortality studies in systemic lupus erythematosus: results from a single center. I. Causes of death. J Rheumatology 1995; 22: 1259–64.
13. Gazi IF, Boumpas DT, Mikhailidis D et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007; 25:102–11.
14. Westerweel PE, Luyten R, Koomans H et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007; 56 (5): 1384–96.
15. Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестн. РАМН 2003; 7: 6–10.
16. Teir J, Koduri G, Meadows A et al. Letter to the editor (other). An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East. Rheumatology 2008; 1–3.
17. Giles J, Post W, Blumenthal R et al. Therapy insight: managing cardiovascular risk in patients with rheumatoid artritis. Nature clin. Practice Rheumatol. 2006; 2 (6): 320–9.
18. Del Rincon I, Williams K, Stern M et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44; 2737–45.
19. Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Науч.-практич. ревматол. 2007; 5: 4–10.
20. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin. Arhritis Rheum 2005; 35: 8–17.
21. Papadopoulos NG, Alamanos Y, Voulgari PV et al. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 2005; 23: 861–6.
22. Попкова Т.В., Новикова Д.С., Герасимова Е.В. и др. Метаболический синдром у больных системной красной волчанкой. Научно-практическая ревматология 2008; 4: 14–20.
23. Dessein P, Joffe B. When is a patient with rheumatoid arthritis as risk for cardiovascular disease? J Rheumatol 2006; 33: 201–3.
24. Sabio JM, Zamora-Pasadas M, Jimenez-Jaimez J et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008; 17: 849–59.
25. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83–6.
26. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра. 2004.
27. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–406.
28. Font J, Ramos-Casals M, Cervera R et al. Cardiovascular risk factors and long-term outcome of lupus nephritis. Q J Med 2001; 9 (4): 19–26.
29. Gonzalez A, Kremers MH, Crowson CS et al. Survival trends and risk factors for mortality in rheumatoid arthritis. Int J of advances in Rheumatol. 2005; 3: 38–46.
30. Radovits BJ, Popa-Diaconu DA, Popa C et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann. Rheum. Dis 2008; 8: 1–15.
31. Bartoloni BE, Marchesi S, Delle Monache F et al. Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity. Rheumatismo 2005; 57 (1): 16–21.
32. Vaudo G, Marchesi S, Gerli R et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63 (1): 31–5.
33. Nielen MJ, van Halm VP, Numohamed MT et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthritis Rheum 2003; 48: 344.
34. Goodson NJ, Symmons DP, Scott DI et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis. Arthritis Rheum 2005; 52 (8): 2293–9.
35. Попкова Т.В., Хелковская А.Н., Мач Э.С. и др. Сердечно-сосудистые заболевания при ревматоидном артрите. Тер. арх. 2007; 5: 9–14.
36. Del Rincon I, Williams K, Stern M et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48 (7); 1833–40.

37. Gonzalez-Juanatey C, Liorca J, Testa A et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407–13.
38. Nagata-Sakurai M, Inaba M, Goto H et al. Inflammation and bone resorbtion as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthr Rheum 2003; 48: 3061–7.
39. Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006; 18 (3): 289–97.
40. Solomon D, Curhan G, Rimm E et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthr Rheum 2004; 50: 344–9.
41. Shoenfeld Y, Gerli R, Doria A et al. Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases. Circulation 2005; 112: 3337–47.
42. Peterson MJ, Symmons DP, McCarrey DW et al. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis – EULAR TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2008; 67 (Suppl II): 310.
43. Оганов Р.Г., Погосова Г.В. Современные стратегии профилактики и лечения сердечно-сосудистых заболеваний. Кардиология 2007; 12: 4 – 9.
44. Scoldstem L, Hagfors L, Johannson J et al. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 208–14.
45. Naranjo A, Sokka T, Descalzo MA et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res. Ther. 2008; 10: R30.
46. Kremers HM, Nicola PJ, Crowson CS. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatism 2004; 11: 3450–57.
47. Turesson C et al. Cardiovascular risk factor, fitness and physical activity in rheumatic disease. Curr Opin Rheumatol 2007; 19: 190–7.
48. Кардиология: национальное руководство. Под ред. Ю.Н.Беленкова, Р.Г.Оганова. М.: Гэотар-Медиа, 2007.
49. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Применение диклофенака и целебрекса у пациентов с артериальной гипертонией, остеоартозом и болями в нижней части спины на фоне гипотензивной терапии Аккупро или Норваском (исследование ДОЦЕНТ). Новости доказательной медицины. www.OSSN.ru
50. Насонов Е.Л. Перспективы применения статинов в ревматологии. РМЖ 2003; 11 (23): 1273–76.
51. McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004; 363: 2015–21.
52. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173–7.
53. Solomon DH, Avorn J, Katz JN. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3790–8.
54. Gonzales-Juataney C, Llorca J, Garcia-Porrua et al. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55: 150–3.
55. Del Porto F, Lagana Bб Lai S et al. Response to anti-tumor necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007; 46: 1111–5.
56. Dixon WG, Watson KD, Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56: 2905–12.
57. Jacobsson LT, Askling J, Rantapaa-Dahlgvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS). Ann Rheum Dis 2008; 67 (suppl II): 183.
58. Jacobsson L.T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213 –1218.
59. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764–70.
60. Del Rincon I, O'Leary DH, Haas RW. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3813–22.
61. Panoulas VF, Metsios GS, Pace AV. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007
62. Bulkley B, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975; 58: 243–64.
63. M.Gonzales-Gay. Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic disease: myth or reality? Arthritis Rheum 2007; 57: 191–2.
64. Hafstrom I, Rohani M, Deneberg S et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis – a randomized study. J Rheumatol 2007; 34: 1810–6.

Т.В.Попкова, Д.С.Новикова, Е.Л.Насонов